CellaVision AB
STO:CEVI
Intrinsic Value
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. [ Read More ]
The intrinsic value of one CEVI stock under the Base Case scenario is 264.47 SEK. Compared to the current market price of 237 SEK, CellaVision AB is Undervalued by 10%.
Valuation Backtest
CellaVision AB
Run backtest to discover the historical profit from buying and selling CEVI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CellaVision AB
Current Assets | 392.5m |
Cash & Short-Term Investments | 167m |
Receivables | 103.2m |
Other Current Assets | 122.3m |
Non-Current Assets | 581.7m |
Long-Term Investments | 3.9m |
PP&E | 126.4m |
Intangibles | 451.3m |
Current Liabilities | 122m |
Accounts Payable | 37.9m |
Other Current Liabilities | 84.1m |
Non-Current Liabilities | 93.3m |
Long-Term Debt | 25.5m |
Other Non-Current Liabilities | 67.8m |
Earnings Waterfall
CellaVision AB
Revenue
|
708.3m
SEK
|
Cost of Revenue
|
-230m
SEK
|
Gross Profit
|
478.2m
SEK
|
Operating Expenses
|
-297.4m
SEK
|
Operating Income
|
180.8m
SEK
|
Other Expenses
|
-39.6m
SEK
|
Net Income
|
141.2m
SEK
|
Free Cash Flow Analysis
CellaVision AB
CEVI Profitability Score
Profitability Due Diligence
CellaVision AB's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
CellaVision AB's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
CEVI Solvency Score
Solvency Due Diligence
CellaVision AB's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Score
CellaVision AB's solvency score is 85/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CEVI Price Targets Summary
CellaVision AB
According to Wall Street analysts, the average 1-year price target for CEVI is 265.2 SEK with a low forecast of 237.35 SEK and a high forecast of 315 SEK.
Shareholder Return
CEVI Price
CellaVision AB
Average Annual Return | -4.62% |
Standard Deviation of Annual Returns | 15.47% |
Max Drawdown | -75% |
Market Capitalization | 5.7B SEK |
Shares Outstanding | 23 851 547 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CellaVision AB engages in the provision of automated microscopy systems in the field of hematology. The company is headquartered in Lund, Skane and currently employs 200 full-time employees. The company went IPO on 2007-05-28. The firm develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision AB’s product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The firm operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Contact
IPO
Employees
Officers
The intrinsic value of one CEVI stock under the Base Case scenario is 264.47 SEK.
Compared to the current market price of 237 SEK, CellaVision AB is Undervalued by 10%.